{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T11:54:11Z","timestamp":1790596451216,"version":"4.1.0"},"reference-count":24,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2015,3,1]],"date-time":"2015-03-01T00:00:00Z","timestamp":1425168000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2015,3,1]],"date-time":"2015-03-01T00:00:00Z","timestamp":1425168000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["cghjournal.org","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Gastroenterology and Hepatology"],"published-print":{"date-parts":[[2015,3]]},"DOI":"10.1016\/j.cgh.2014.07.062","type":"journal-article","created":{"date-parts":[[2014,8,15]],"date-time":"2014-08-15T03:27:28Z","timestamp":1408073248000},"page":"602-608","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":118,"title":["Risk of Drug-Induced Liver Injury From Tumor Necrosis Factor Antagonists"],"prefix":"10.1016","volume":"13","author":[{"given":"Einar S.","family":"Bj\u00f6rnsson","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Baldvin I.","family":"Gunnarsson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gerdur","family":"Gr\u00f6ndal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jon G.","family":"Jonasson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rannveig","family":"Einarsdottir","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bj\u00f6rn R.","family":"Ludviksson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bj\u00f6rn","family":"Gudbj\u00f6rnsson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sigurdur","family":"Olafsson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.cgh.2014.07.062_bib1","doi-asserted-by":"crossref","first-page":"84","DOI":"10.4065\/76.1.84","article-title":"Infliximab-associated reversible cholestatic liver disease","volume":"76","author":"Menghini","year":"2001","journal-title":"Mayo Clin Proc"},{"key":"10.1016\/j.cgh.2014.07.062_bib2","doi-asserted-by":"crossref","first-page":"1966","DOI":"10.1002\/1529-0131(200108)44:8<1966::AID-ART339>3.0.CO;2-3","article-title":"Hepatitis with interface inflammation and IgG, IgM, and IgA anti-double-stranded DNA antibodies following infliximab therapy: comment on the article by Charles, et\u00a0al","volume":"44","author":"Saleem","year":"2001","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.cgh.2014.07.062_bib3","doi-asserted-by":"crossref","first-page":"1519","DOI":"10.1136\/ard.2004.032821","article-title":"Autoimmune hepatitis associated with infliximab in a patient with psoriatic arthritis","volume":"64","author":"Germano","year":"2005","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.cgh.2014.07.062_bib4","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1007\/s10067-005-0169-y","article-title":"Serious liver disease induced by infliximab","volume":"26","author":"Tobon","year":"2007","journal-title":"Clin Rheumatol"},{"key":"10.1016\/j.cgh.2014.07.062_bib5","doi-asserted-by":"crossref","first-page":"1063","DOI":"10.1007\/s10067-008-0885-1","article-title":"A\u00a0case of autoimmune hepatitis exacerbated by the administration of etanercept in the patient with rheumatoid arthritis","volume":"27","author":"Harada","year":"2008","journal-title":"Clin Rheumatol"},{"key":"10.1016\/j.cgh.2014.07.062_bib6","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1016\/j.jbspin.2007.12.009","article-title":"Infliximab-induced hepatitis: absence of cross-toxicity with etanercept","volume":"75","author":"Thi\u00e9fin","year":"2008","journal-title":"Joint Bone Spine"},{"key":"10.1016\/j.cgh.2014.07.062_bib7","doi-asserted-by":"crossref","first-page":"524","DOI":"10.5694\/j.1326-5377.2007.tb01396.x","article-title":"Autoimmune hepatitis following infliximab therapy for ankylosing spondylitis","volume":"187","author":"Ozorio","year":"2007","journal-title":"Med J Aust"},{"key":"10.1016\/j.cgh.2014.07.062_bib8","doi-asserted-by":"crossref","first-page":"e43","DOI":"10.1016\/j.jaad.2009.02.029","article-title":"Autoimmune hepatitis in two psoriasis patients treated with infliximab","volume":"63","author":"Goujon","year":"2010","journal-title":"J\u00a0Am Acad Dermatol"},{"key":"10.1016\/j.cgh.2014.07.062_bib9","doi-asserted-by":"crossref","first-page":"e20","DOI":"10.1097\/MCG.0b013e3181a745e7","article-title":"Adalimumab-induced autoimmune hepatitis","volume":"44","author":"Adar","year":"2010","journal-title":"J\u00a0Clin Gastroenterol"},{"key":"10.1016\/j.cgh.2014.07.062_bib10","doi-asserted-by":"crossref","first-page":"e7","DOI":"10.1016\/j.gcb.2010.01.016","article-title":"Infliximab-induced acute hepatitis during Crohn's disease therapy: absence of cross-toxicity with adalimumab","volume":"34","author":"Haennig","year":"2010","journal-title":"Gastroenterol Clin Biol"},{"key":"10.1016\/j.cgh.2014.07.062_bib11","doi-asserted-by":"crossref","first-page":"100","DOI":"10.2310\/7750.2009.09007","article-title":"Drug-induced hepatitis and lupus during infliximab treatment for psoriasis: case report and literature review","volume":"14","author":"Poulin","year":"2010","journal-title":"J\u00a0Cutan Med Surg"},{"key":"10.1016\/j.cgh.2014.07.062_bib12","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1007\/s00228-011-1191-4","article-title":"Autoimmune hepatitis induced by adalimumab with successful switch to abatacept","volume":"68","author":"Grasland","year":"2012","journal-title":"Eur J Clin Pharmacol"},{"key":"10.1016\/j.cgh.2014.07.062_bib13","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1016\/j.cgh.2012.12.025","article-title":"Liver injury from tumor necrosis factor-\u03b1 antagonists: analysis of thirty-four cases","volume":"11","author":"Ghabril","year":"2013","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.cgh.2014.07.062_bib14","doi-asserted-by":"crossref","first-page":"2192","DOI":"10.1002\/art.21190","article-title":"Infliximab, but not etanercept, induces IgM anti-double-stranded DNA autoantibodies as main antinuclear reactivity: biologic and clinical implications in autoimmune arthritis","volume":"52","author":"De Rycke","year":"2005","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.cgh.2014.07.062_bib15","doi-asserted-by":"crossref","first-page":"1695","DOI":"10.1136\/annrheumdis-2014-205318","article-title":"What is the utility of routine ANA testing in predicting development of biological DMARD-induced lupus and vasculitis in patients with rheumatoid arthritis? Data from a single-centre cohort","volume":"73","author":"Takase","year":"2014","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.cgh.2014.07.062_bib16","doi-asserted-by":"crossref","first-page":"1419","DOI":"10.1053\/j.gastro.2013.02.006","article-title":"Incidence, presentation and outcomes in patients with drug-induced liver injury in the general population of Iceland","volume":"144","author":"Bjornsson","year":"2013","journal-title":"Gastroenterology"},{"key":"10.1016\/j.cgh.2014.07.062_bib17","doi-asserted-by":"crossref","first-page":"1323","DOI":"10.1016\/0895-4356(93)90101-6","article-title":"Causality assessment of adverse reactions to drugs-I. A novel method based on the conclusions of international consensus meetings: application to drug-induced liver injuries","volume":"46","author":"Danan","year":"1993","journal-title":"J\u00a0Clin Epidemiol"},{"key":"10.1016\/j.cgh.2014.07.062_bib18","doi-asserted-by":"crossref","first-page":"R1063","DOI":"10.1186\/ar1787","article-title":"DAS28 best reflects the physician\u2019s clinical judgment of response to infliximab therapy in rheumatoid arthritis patients: validation of the DAS28 score in patients under infliximab treatment","volume":"7","author":"Vander Cruyssen","year":"2005","journal-title":"Arthritis Res Ther"},{"key":"10.1016\/j.cgh.2014.07.062_bib19","doi-asserted-by":"crossref","first-page":"2003","DOI":"10.1002\/hep.22272","article-title":"Relationship between daily dose of oral medications and idiosyncratic drug-induced liver injury (DILI). Search for signals","volume":"47","author":"Lammert","year":"2008","journal-title":"Hepatology"},{"key":"10.1016\/j.cgh.2014.07.062_bib20","doi-asserted-by":"crossref","first-page":"2001","DOI":"10.1002\/hep.22895","article-title":"Phenotypic characterization of idiosyncratic drug-induced liver injury: the influence of age and sex","volume":"49","author":"Lucena","year":"2009","journal-title":"Hepatology"},{"key":"10.1016\/j.cgh.2014.07.062_bib21","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1002\/hep.22322","article-title":"Simplified criteria for the diagnosis of autoimmune hepatitis","volume":"48","author":"Hennes","year":"2008","journal-title":"Hepatology"},{"key":"10.1016\/j.cgh.2014.07.062_bib22","doi-asserted-by":"crossref","first-page":"2040","DOI":"10.1002\/hep.23588","article-title":"Drug-induced autoimmune hepatitis: clinical characteristics and prognosis","volume":"51","author":"Bj\u00f6rnsson","year":"2010","journal-title":"Hepatology"},{"key":"10.1016\/j.cgh.2014.07.062_bib23","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1007\/s002960050058","article-title":"Management of cutaneous lupus erythematosus with low-dose methotrexate: indication for modulation of inflammatory mechanisms","volume":"18","author":"Boehm","year":"1998","journal-title":"Rheumatol Int"},{"key":"10.1016\/j.cgh.2014.07.062_bib24","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1016\/S1568-9972(03)00017-X","article-title":"Autoimmune hepatitis","volume":"2","author":"Vergani","year":"2003","journal-title":"Autoimmun Rev"}],"container-title":["Clinical Gastroenterology and Hepatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1542356514011513?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1542356514011513?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T05:15:51Z","timestamp":1761542151000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1542356514011513"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,3]]},"references-count":24,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2015,3]]}},"alternative-id":["S1542356514011513"],"URL":"https:\/\/doi.org\/10.1016\/j.cgh.2014.07.062","relation":{},"ISSN":["1542-3565"],"issn-type":[{"value":"1542-3565","type":"print"}],"subject":[],"published":{"date-parts":[[2015,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Risk of Drug-Induced Liver Injury From Tumor Necrosis Factor Antagonists","name":"articletitle","label":"Article Title"},{"value":"Clinical Gastroenterology and Hepatology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cgh.2014.07.062","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2015 AGA Institute. Published by Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}